James F Oliviero Iii Checkpoint Therapeutics, Inc. (CKPT) insider trading activity

James F Oliviero Iii is CEO, President and Director of Checkpoint Therapeutics, Inc.. Currently has a direct ownership of 0 shares of CKPT, which is worth approximately $0. The most recent transaction as insider was on Jun 17, 2022, when has been sold 228,000 shares (Common Stock) at a price of $1.09 per share, resulting in proceeds of $248,520. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

James F Oliviero III Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 17 2022	SELL Open market or private sale	$248,520 $1.09 p/Share	228,000 Reduced 8.03%	2,610,003 Common Stock
Apr 13 2022	SELL Open market or private sale	$32,100 $1.51 p/Share	21,258 Reduced 0.74%	2,838,003 Common Stock
Apr 05 2022	SELL Open market or private sale	$24,833 $1.77 p/Share	14,030 Reduced 0.49%	2,859,261 Common Stock
Apr 04 2022	SELL Open market or private sale	$154,572 $1.79 p/Share	86,353 Reduced 2.92%	2,873,291 Common Stock
Feb 24 2022	SELL Payment of exercise price or tax liability	$217,665 $1.85 p/Share	117,657 Reduced 3.82%	2,959,644 Common Stock
Jan 31 2022	BUY Grant, award, or other acquisition	-	455,000 Added 11.2%	3,608,210 Common Stock (restricted)
Jan 30 2022	SELL Payment of exercise price or tax liability	$78,651 $2.46 p/Share	31,972 Reduced 1.03%	3,077,301 Common Stock
Jan 24 2022	SELL Payment of exercise price or tax liability	$313,468 $2.19 p/Share	143,136 Reduced 4.4%	3,109,273 Common Stock
Jan 06 2022	SELL Payment of exercise price or tax liability	$146,876 $2.77 p/Share	53,024 Reduced 1.6%	3,252,409 Common Stock
Jan 01 2022	SELL Payment of exercise price or tax liability	$941,636 $3.11 p/Share	302,777 Reduced 8.39%	3,305,433 Common Stock
Feb 05 2021	SELL Open market or private sale	$166,862 $3.42 p/Share	48,790 Reduced 1.52%	3,153,210 Common Stock
Feb 04 2021	SELL Open market or private sale	$245,700 $3.51 p/Share	70,000 Reduced 2.14%	3,202,000 Common Stock
Jan 06 2021	BUY Grant, award, or other acquisition	-	539,000 Added 14.14%	3,272,000 Common Stock (restricted)

Also insider at

NVCT

Nuvectis Pharma, Inc. Healthcare

Director

JFO